Research led by the Department of Pathology at Stanford University, California, has found that chimeric antigen receptor T (CAR T) cell therapy can potentially result in a reactivation of human herpesvirus 6 (HHV-6) by CAR ...
For just the second time ever an HIV patient is in sustained remission from the virus in what was hailed by experts Tuesday as proof that the AIDS-causing condition could one day be curable.
Mar 5, 2019
0
562
Immune cells undergo 'spontaneous' changes on a daily basis that could lead to cancers if not for the diligent surveillance of our immune system, Melbourne scientists have found.
Feb 2, 2014
1
0
How do you annihilate lymphoma without using any drugs? Starve it to death by depriving it of what appears to be a favorite food: HDL cholesterol.
Jan 21, 2013
1
1
A team led by researchers at Weill Cornell Medicine has identified important drivers of the transformation of a type of blood cancer called follicular lymphoma from a slow-growing form to the aggressive form it takes in some ...
Mar 28, 2024
0
13
Chimeric antigen receptor T-cell therapy, or CAR T, has dramatically improved the treatment of certain blood cancers. Initially approved for patients who had failed multiple lines of therapy, clinical trials have shown CAR ...
Jan 17, 2024
0
36
A Stanford Medicine-led, international study of hundreds of samples from patients with Hodgkin lymphoma has shown that levels of tumor DNA circulating in their blood can identify who is responding well to treatment and others ...
Dec 11, 2023
0
38
Northwestern Medicine investigators have discovered how the protein PD-1 controls essential metabolic processes in tumor cells to promote cancer growth in T-cell non-Hodgkin lymphomas (T-NHLs), according to a study published ...
Sep 21, 2023
0
26
Anaplastic large cell lymphoma, a form of non-Hodgkin lymphoma, is the most common aggressive lymphoma in children. Chemotherapy and radiation fail to cure about 30% of cases. When tumors are driven by the oncogene ALK—which ...
Aug 3, 2023
0
22
Patients with early relapsed or refractory large B-cell lymphoma had significantly improved overall survival when treated with the chimeric antigen receptor (CAR) T cell therapy axicabtagene ciloleucel (axi-cel) when compared ...
Jun 5, 2023
0
33
